LEL Lilly(Eli)

 
TIDMLEL 
 
Date: June 4, 2012 
 
For Release: Immediately 
 
Refer to: (317) 276-5795 - Mark E. Taylor 
 
         Dr. William G. Kaelin Jr. Elected to Lilly Board of Directors 
 
The Board of Directors of Eli Lilly and Company (NYSE:LLY) has elected William 
G. Kaelin Jr., M.D. as a new member, effective June 4, 2012. Dr. Kaelin, 54, is 
a Professor in the Department of Medicine at Dana-Farber Cancer Institute and 
Brigham and Women's Hospital, Senior Physician at Brigham and Women's Hospital, 
and Associate Director, Basic Science, at the Dana-Farber/Harvard Cancer 
Center.  As a member of Lilly's board, Dr. Kaelin will serve on the science and 
technology committee and the finance committee. He will serve under interim 
election to fill a vacancy left by the retirement of Dr. Martin Feldstein and 
will stand for election by Lilly shareholders at the company's annual meeting 
in May, 2014. 
 
"I am very pleased to welcome Dr. Bill Kaelin to the Lilly board. Dr. Kaelin's 
deep scientific knowledge and medical expertise will benefit Lilly shareholders 
and the patients who depend on us," commented John Lechleiter, Ph.D., Lilly 
chairman, president and chief executive officer. "Bill is a leading cancer 
researcher and has a clear appreciation of the importance of scientific 
research and of Lilly's commitment to the discovery and development of 
innovative medicines that make a difference for patients." 
 
Dr. Kaelin received his medical degree from Duke University in 1982 and was a 
house officer in internal medicine at Johns Hopkins Hospital. He went on to 
become a medical oncology clinical fellow at the Dana-Farber Cancer Institute 
and a postdoctoral fellow in the laboratory of Dr. David Livingston, where he 
began his studies of tumor suppressor proteins. He became an independent 
investigator at Dana-Farber Cancer Institute in 1992 as a James S. McDonnell 
Scholar and became a Howard Hughes Medical Institute investigator in 1998. 
 
Dr. Kaelin's research interests have focused on tumor suppressor genes and the 
normal functions of the proteins they encode. The long-term goal of his work is 
to lay the foundation for the development of new anticancer therapies based on 
the functions of specific tumor suppressor proteins. His studies of tumor 
suppressor genes linked to hereditary forms of cancer have uncovered molecular 
pathways that are important in non-hereditary cancers and have accelerated the 
development of new treatments for kidney cancer. 
 
Dr. Kaelin is an elected member of the Institute of Medicine and the National 
Academy of Sciences and has served on numerous boards and committees, including 
the American Association for Cancer Research's Board of Directors and the 
National Cancer Institute Board of Scientific Advisors. He has received many 
awards for his work, including the Canada Gairdner International Prize, the 
AACR-Richard and Hinda Rosenthal Prize for Cancer Research, and the Paul Marks 
Prize for Cancer Research from Memorial Sloan-Kettering Cancer Center. Most 
recently, he was named co-recipient of the Scientific Grand Prize 2012 of the 
Lefoulon-Delalande Foundation. 
 
About Lilly 
 
Lilly, a leading innovation-driven corporation, is developing a growing 
portfolio of pharmaceutical products by applying the latest research from its 
own worldwide laboratories and from collaborations with eminent scientific 
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - 
through medicines and information - for some of the world's most urgent medical 
needs. Additional information about Lilly is available at www.lilly.com. 
 
C-LLY 
 
 
 
Eli Lilly and Company 
 
Lilly Corporate Center 
 
Indianapolis, Indiana 46285 
 
U.S.A. 
 
www.lilly.com 
 
 
 
 
 
 
 
                                     - 2 - 
 
 
 
 
END 
 

Lilly(Eli) (LSE:LEL)
Historical Stock Chart
From Jan 2025 to Feb 2025

Lilly(Eli) (LSE:LEL)
Historical Stock Chart
From Feb 2024 to Feb 2025